The Anti-Fibrotic Drug Development Summit is the first meeting to assemble researchers and program leaders from cross-industry to share experiences and insights on how to better directly target the fibrotic and inflammatory drivers of these devastating diseases.

Developed in combination with experts from GSK, BMS, Pfizer and many more this forum aims to better elucidate how the underlying fibrotic biology can be more effectively drugged, to discern which models of fibrosis are the most robust and how biomarkers can be implemented into improved clinical trials designs.